Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

venetoclax 45Cyclophosphamide 43Specimen Handling 41Cytarabine 39fludarabine 31Biopsy 30Azacitidine 24Rituximab 20Methotrexate 17fludarabine phosphate 16blinatumomab 15Vincristine 15Dexamethasone 14Daunorubicin 14ibrutinib 13Prednisone 13Magnetic Resonance Spectroscopy 13Whole-Body Irradiation 12Injections 12obinutuzumab 11merphos 11Mercaptopurine 11Calcium Dobesilate 11Mycophenolic Acid 10Filgrastim 10Doxorubicin 10X-Rays 9Tacrolimus 9Leucovorin 9Etoposide 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
benralizumab × Other hematologic neoplasm × 30 days × Clear all
NCT04552288 2026-06-01

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
51 enrolled 8 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡